Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids
January 28, 2013 9:02 AM ESTDeutsche Bank downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold following takeover deal. The firm doesn't expect other bids.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For... More
Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform
January 24, 2013 6:54 AM ESTLeerink Swann downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Market Perform with a price target of $25.00 (from $19.00) following yesterday's takeover deal.
"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device... More
Allergan (AGN) Acquires MAP Pharmaceuticals (MAPP) for $958M
January 23, 2013 6:34 AM ESTAllergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or approximately $958 million. The offer represents a 60% premium over MAPs closing stock price on the Nasdaq Stock Market of $15.58 on January 22, 2013.
The acquisition is expected to close late in the first quarter or in the second quarter of 2013.
In January 2011, Allergan entered into... More
